---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-018790"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:35:28.393665+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics reports Q1 net loss of $53.1M; exa-cel submissions complete in US, EU, UK

## Summary
- Revenue of $100.0M from Vertex upfront; net loss improved to $53.1M vs $179.2M in Q1 2022.
- Cash and securities $1,889.5M; R&D expenses $99.9M, G&A $22.4M.
- Completed rolling BLAs for exa-cel in SCD and TDT; EMA and MHRA submissions validated.
- Initiated clinical trials for next-gen CAR T candidates CTX112 (CD19) and CTX131 (CD70).
- Appointed Raju Prasad as CFO; Brad Bolzon left board; Vertex deal includes $100M upfront and up to $230M milestones.

## SEC filing metadata
- accession: 0000950170-23-018790
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/0000950170-23-018790-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/crsp-20230508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-018790
- JSON: https://secwatch.observer/filing/0000950170-23-018790.json
- Plain text: https://secwatch.observer/filing/0000950170-23-018790.txt

## Key facts
- Earnings Releases
  CRISPR Therapeutics AG reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1674416/000095017023018790/0000950170-23-018790-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.